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Background: Yi Guan Jian Decoction (YGJD), a famous Chinese prescription, has long been employed clinically to
treat liver fibrosis. However, as of date, there is no report on the effects of YGJD from a metabonomic approach. In
this study, a urine metabonomic method based on gas chromatography coupled with mass spectrometry (GC/MS)
was employed to study the protective efficacy and metabolic profile changes caused by YGJD in carbon
tetrachloride (CCl4)-induced liver fibrosis.
Methods: Urine samples from Wistar rats of three randomly divided groups (control, model, and YGJD treated)
were collected at various time-points, and the metabolic profile changes were analyzed by GC/MS with principal
component analysis (PCA) and partial least squares-discriminate analysis (PLS-DA). Furthermore, histopathology and
biochemical examination were also carried out to ensure the success of CCl4-induced liver fibrosis model.
Results: Urine metabolic profile studies suggested distinct clustering of the three groups, and YGJD group was
much closer to the control group by showing a tendency of recovering towards the control group. Fourteen
significantly changed metabolites were found, and YGJD treatment could reverse the levels of these metabolites to
normal levels or close to normal levels.
Conclusions: The current study indicates that the YGJD has significant anti-fibrotic effects on CCl4-induced liver
fibrosis in rats, which might be by regulating the dysfunction of energy metabolism, amino acid metabolism,
tryptophan metabolism, cytochrome P450 metabolism, and gut microflora metabolism. The metabonomic approach
can be recommended to study the pharmacological effect and mechanism of complex Chinese medicines.
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Liver fibrosis is a characteristic of most types of chronic
liver diseases. A number of factors such as viral infections
(hepatitis B and C), alcoholism, autoimmune diseases and
nonalcoholic fatty liver disease etc., may cause liver fibro-
sis [1], which corresponds to an increased production of
extracellular matrix components(collagens in particular)
and leads to liver dysfunction and cirrhosis [2,3]. With the
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reproduction in any medium, provided the ordynamic and bi-directional process [4]. However, cirrhosis,
the end-stage consequence of fibrosis, is generally irrever-
sible. Nevertheless, no curative treatment for liver fibrosis is
available until today [5]. It is imperative to explore treat-
ment options and discover more effective drugs against
fibrosis and its severe consequences [6]. With a long history
in the treatment of diseases, Traditional Chinese Medicine
(TCM) are gaining popularity among patients with liver
diseases and as effective putative antifibrotic agents [7,8].
Yi Guan Jian Decoction (YGJD), a classical TCM for-
mula, is composed of Radix glehniae, Radix ophiopogonis,
Radix angelicae sinensis, Radix rehmannia, Fructus lycii
and Fructus toosendan. A recent study has indicated the
hepatoprotective and antifibrotic effects of YGJD against. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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suppressed the elevation of serum glutamate oxaloacetate
transaminase (GOT) and serum glutamic pyruvic trans-
aminase (GPT) and significantly reduce the accumulation
of collagen α1-I, tissue inhibitor of metalloproteinase −1
(TIMP)-1 and alpha-smooth muscle actin (α-SMA) in
liver tissues [9]. It significantly inhibited carbon tetrachlo-
ride (CCl4)-induced liver fibrosis and cirrhosis in rats,
which might be associated with decrease in the liver
content of hydroxyproline, α-SMA mRNA and Afamin
mRNA expression [10,11]. Until now, a number of re-
searches have been centered on the mechanism and
efficacy of YGJD. But, little attention has been changed on
the entire endogenous metabolites in YGJD processing or-
ganism. Moreover, the major active constituents of YGJD,
ferulic acid and catalpol, significantly inhibited the pro-
gression of CCl4-induced hepatic fibrosis induced in rats
[12]. These constituents may contribute to understand the
protective efficacy and therapeutic mechanism of YGJD.
Metabonomics is a relatively new science and is an
important branch of systems biology. It is defined as “the
quantitative measurement of the dynamic multiparametric
metabolic response of living systems to pathophysiologic
stimuli or genetic modification” [13]. Metabonomics in-
volves the analysis of endogenous metabolites of various
biofluids and tissues, and harvests a latent relationship
between the changed metabolic profiles and the physio-
logical status of the biosystems [14]. This research strategy
complies well with the integrity and systemic feature of
TCM. Metabonomic technique has shown immense
promise and has been applied to various domains [15],
such as drug toxicity studies [16], drug efficacy studies
[17], biomarker studies, and clinical diagnosis of diseases
[18] etc. Some of the different analytical techniques
currently in use include hydrogen-1 nuclear magnetic
resonance, high-performance liquid chromatography/mass
spectrometry, fourier transform infrared spectroscopy,
and gas chromatography/mass spectrometry (GC/MS)
[19]. Among them, GC/MS is a robust, unbiased method
in identifying and quantifying metabolites with high sensi-
tivity, simplicity, high reproducibility and NIST database
accessibility [20,21]. It has gained the potential to become
a powerful tool for metabonomic analysis of urine samples
[22]. The present study investigated the urine metabolic
profiles changes of CCl4-induced liver fibrosis in rats and
studied the intervention effects of YGJD using a GC/MS
based metabonomic technique. With the perturbed me-
tabolites, attempts were made to explore the possible
therapeutic mechanism of YGJD.
Methods
Reagents
Ethyl chloroformate, pyridine, anhydrous ethanol, sodium hy-
droxide, chloroform, CCl4, olive oil, isopropanol, anhydroussodium acetate, methanol and anhydrous sodium fulfate
were of analytical grade and were obtained from China
National Pharmaceutical Group Corporation (Shanghai,
China). L-2-chlorophenylalanine (Shanghai IntechemTech.
Co. Ltd., China) was used as an internal quality standard.
Hydroxyproline was from Japan ナ カ Te ィ Te Su Ku
Ltd., (Tokyo, Japan), and perchloric acid was from Shanghai
Jinglu Chemical Co. Ltd., (Shanghai, China). Commercial
kits used for determining AST, ALT, Alb, GGT and TBil
were obtained from Nanjing Jiancheng Institute of Biotech-
nology (Nanjing, China).
YGJD Preparation
YGJD was prepared using the method proposed by
Yongping Mu et al. [12]. The following six dried raw
herbs were purchased from Shanghai Huayu Chinese
Herbs Co. Ltd., (Shanghai, China): 1.0 kg of Radix
glehniae, 1.0 kg of Radix ophiopogonis, 1.0 kg of Radix
angelicae sinensis, 1.8 kg of Radix rehmannia, 1.2 kg of
Fructus lycii and 0.45 kg of Fructus toosendan. The
mixture was decocted twice with boiling water (1.5 h each
time). The decoction was then filtered, mixed and concen-
trated under reduced pressure to fluid extract, which was
dried under vacuum to afford 4.27 kg of dry powder and
stored in cold preservation until use.
Animals
Male Wistar rats of weight 140 g to 150 g were obtained
from Shanghai Experimental Animal Center of Chinese
Academy of Sciences. Animal foods were commercially
obtained from Shanghai Laboratory Animal Center.
(Shanghai, China). All rats were housed individually under
set temperature (20 ± 5°C) and humidity (50 ± 10%) with a
12/12 h-light/dark cycle. The animals were provided with
common food and water ad libitum. The experimental
procedures were approved by the Ethics Committee of the
Institute of Shanghai University of TCM.
CCl4-induced live fibrosis
After an initial acclimation period of 2 weeks in cages,
CCl4 (1 mL/kg 50% CCl4, diluted in olive oil, twice each
week) was injected intraperitoneally (IP)for 9 weeks to
induce rat live fibrosis as described by Nakamura T and
colleagues [23].
Treatment groups
After treatment with CCl4 for 6 weeks, the model rats were
randomly divided into 2 groups: model group (n = 10),
YGJD group (n = 11). YGJD group was oral administrated
at dosage 2.682 g/kg body weight of YGJD, diluted in water,
intragastric administration (IG), once a day for 3 weeks,
and concomitantly received CCl4 treatment. A control
group rats (n = 6) and model group were orally adminis-
trated with same volume of saline solution.
Figure 1 Effect of YGJD on serum levels of AST, ALT (A) and
GGT, Alb, TBiL (B) in CCl4-induced liver fibrosis in rats. Values
are expressed as mean ± SD. ** compared with the control group,
P < 0.01; ## compared with model group, P < 0.01.
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Urine samples at 12 h were collected during week 0
before CCl4 injection and week 1, 6, 8 and 9 after CCl4
injection. All collected urine samples were immediately
stored at -80°C before GC/MS analysis. After the final
collection time point, all animals were anesthetized with
sodium pentobarbital (2 mL/kg, IP) and sacrificed by
cervical dislocation. Blood samples were obtained from
the abdominal aorta and centrifuged at 3000 rpm for
10 min to obtain serum. Livers were isolated and stored
at −80°C for pathological observation.
Analysis of liver function
Serum alanine aminotransferase (ALT), aspartate amino-
transferase (AST), total bilirubin (TBil), albumin(Alb)
and γ-glutamyl traspeptidase(GGT) were determined to
assess liver function using commercially available kits
(Nanjing Jiancheng Institute of Biotechnology, China)
according to manufacturer’s instructions.
Measurement of hepatic hydroxyproline contents
Hepatic hydroxyproline contents were measured by the
method of Jamall and colleagues [24], and the results
were expressed as μg/mg wet tissue.
Histology
A portion of each liver was fixed in 10% neutral forma-
lin, dehydrated and embedded in paraffin. The samples
were stained with hematoxylin and eosin (HE) and sirius
red staining for histological examination per standard
procedure. Fibrosis was graded by Li C et al. [25] as fol-
lows: grade 0-no fibrosis, normal liver; grade I-fibrosis
present; grade II-mild fibrosis; grade III- moderate fibro-
sis; and grade IV- severe fibrosis.
Urine sample preparation and GC/MS analysis
The urine sample preparation and GC/MS analysis were
performed as described by Qiu Y et al. [26], which were
shown in the Additional file 1.
Data analysis
All raw data were converted to document format, and
then processed by the XCMS (http://metlin.scripps.edu/
download/) with default settings to carry out baseline cor-
rection, peak discrimination and alignment. The result
was exported into Microsoft Excel 2007, where each peak
was normalized to the total sum of peaks. The resulted
three-dimensional data involving the peak number, sample
name, and normalized peak area were fed to SIMCA-P
11.5 software package(Umetrics, Umea, Sweden) for prin-
cipal component analysis (PCA) and partial least squares
discriminant analysis (PLS-DA) after undertaking a unit
variance procedure. The concentrations of the significantlychanged metabolites were represented as their relative
areas (divided by the area of internal standard).Statistics
Quantitative data was presented as means +/− SD. Statis-
tical analysis was analyzed by one-way analysis of variance
with Student–Newman–Keuls test using the SPSS17.0
software (SPSS, Chicago, USA. Histological grade from
the liver were evaluated using Ridit analysis. P < 0.05 was
considered statistically significant.Results
Liver function tests in serum
As shown in Figure 1, the levels of AST, ALT, GGT and
TBil in serum were significantly increased in model
group compared with control group (P < 0.01), but they
were significantly decreased in the YGJD group com-
pared with model group (P < 0.01). Serum Alb content
in model group was significantly lower than that in the
control group (P < 0.01). YGJD could elevate Alb content
and there was significant difference compared with the
control group (P < 0.01).Hepatic hydroxyproline content
In model group, hepatic hydroxyproline content was
approximately increased 5 times over the control group
(P < 0.01). However, the hydroxyproline concentration
was significantly decreased in YGJD group after YGJD
administeration (P < 0.01) (Figure 2).
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As shown in Figure 3, HE staining and sirius red staining
of liver sections were observed for histological changes.
Liver tissue samples from the control group showed an
intact liver tissue structure with little collagen deposition
(Figure 3A and D). The liver tissue samples from the
model group exhibited more fatty degeneration, more
steatosis, cell necrosis, and infiltration of inflammatory
cells and there were more collagen deposition compared
with the control group (Figure 3B and E). In YGJD
group, however, liver fibrosis symptoms were all appa-
rently ameliorated and collagen deposition was also mark-
edly reduced compared with the model group, (Figure 3C
and F). The model group rats had a high degree of fibrosis
compared with the control group (P < 0.05), and treatment
with YGJD significantly decreased histological grade in
YGJD group compared with the model group (P < 0.05)
(Table 1).
Metabonomics
1) GC/MS spectra of the three groupsFig
in l
com
moThe typical GC/MS total ion current (TIC)
chromatograms of rat urine on 9th week from the
control, model and YGJD groups are shown in
Figure 4. There are obvious changes in both the
control and model groups, while, the spectra are
similar between control group and YGJD group.
Based on NIST database and reference standards,
the most peaks were identified as endogenousure 2 Effect of YGJD on the hepatic hydroxyproline content
iver fibrosis rats. Values are the mean ± SD. ** P < 0.01
pared with the control group; ## P < 0.01 compared with the
del group.metabolites, which including the following: amino
acids, organic acids and fatty acids. These
metabolites were mainly involved in energy
metabolism, lipid metabolism and amino acid
metabolism. In order to illustrate the differences of
the metabolic profiles, GC/MS spectra were further
pre-treated and a pattern recognition analysis was
carried out.2) Analysis of metabolic profiles
In order to understand the general trends,
differences and outliers among three groups by GC/
MS spectra, the 9th week sample was selected owing
to the greatest degree of pathological changes in rats
and a PCA was carried out. The result showed
unsatisfactory separation in the scores plot among
three groups (figure not shown).
To obtain a higher level of group separation and
enhance recognition of variables responsible for
classification, a supervised PLS-DA was applied. The
obtained 3D-PLS-DA score plot (Figure 5) showed
better separation than PCA among three groups.
From the 3D-PLS-DA score plot, a separation of the
model group and control group was clearly
achieved. The YGJD group was mainly located
between the model group and the control group,
and it exhibited a tendency to recover to control
group. A 7-fold cross-validation was used to
estimate the robustness and the predictive ability of
our model [27], and the parameters for the
classification from the software were R2Y = 0.90 and
Q2Y = 0.48, which were stable and good to fitness
and prediction, respectively. A permutation test was
proceeded in order to further validate the model
[28]. The R2 and Q2 intercept values were 0.51 and
−0.35 after 200 permutations. The negative values of
Q2 intercept indicate the robustness of the models,
and thus show a low risk of over fitting and reliable
(Figure 6). These results demonstrate that YGJD
treatment could restore the disturbed metabolic
profiles of rats.3) Changed metabolites analysis of urine samples
Based on the3D-PLS-DA, a loading plot was
constructed, which showed the contribution of
variables to difference among three groups. It also
showed the important variables which were situated
far from the origin but the loading plot is complex
because of many variables (figure not shown).
To refine this analysis, the variable importance
projection (VIP) was obtained [28]. The VIP values
exceeding 1.0 were first selected as changed
metabolites. In step 2, the remaining variables were
then assessed by t test, P > 0.05, variables were
Figure 3 Histological changes of liver tissues as shown by HE staining (×200) and Sirius Red staining (×200). (A)-(C) HE staining; (A)
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Additionally, significantly changed metabolites
detected were identified by using the reference
compounds available and the commercial compound
database of NIST. Meanwhile, the metabolites were
interpreted for related pathway with the available
biochemical databases, such as KEGG (http://www.
genome.jp/kegg/), HMDB (http://www.hmdb.ca/).
On the basis of the above analysis, 14 variablese 1 Effect of YGJD on the pathologic grading of
-induced liver fibrosis in rats
p n Pathologic grading of liver fibrosis P value
0 I II III IV
ol group 6 6 0 0 0 0 -
l group 10 0 0 0 6 4 a
group 11 0 0 7 4 0 b
ical analysis of the data for comparisons of the pathological grading was
med by Ridit analysis; Figures represent number of rat per grade;
0.05, compared with control group; b: P < 0.05, compared with
l group.representing individual metabolites as significantly
changed metabolites were listed out. These
metabolites are shown in Table 2.
In particular, compared with the control group, the
model group displayed increased levels of
metabolites, including butanedioic acid, indole-3
-carboxylic acid, citrate, hippuric acid, glutamate,
and hexadecanoic acid, and decreased levels of
glycine, leucine, phenol, proline, oleic acid,
octadecenoic acid, lysine, and tryptophan.
Furthermore, it was shown that the concentration
alterations of the metabolites in YGJD group were
all properly regulated when compared with the
model group, and there were non-significant except
for octadecenoic acid and lysine when compared
with the control group. These results confirmed that
the disturbed urine metabolite profiles owing to
CCl4 exposure were regulated by YGJD. The results
of liver function tests, histological changes, and
these change in urine metabolic pattern showed that
liver fibrosis was being prevented and alleviated after
taking YGJD.
Figure 4 Typical GC/MS TIC chromatograms of rat urine samples obtained from the three groups. A: control group, B: model group, C: YGJD group.
Figure 5 Score plot of 3D-PLS-DA model obtained from control
group (●), model group (red bullet) and YGJD group (blue bullet).
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YGJD group
The time-related trajectory of metabolic patterns
were obtained from the mean scores value of PC1
and PC2 at week 0 before CCl4 injection, week 1, 6,
8, and 9 after CCl4 injection (Figure 7). In the scores
plot of PCA, no apparent changes of metabolic
profile were observed in the control group. In the
model group, the metabolic pattern at different time
points showed distinct differences, and a tendency of
deviating from time point of week 0 pre-dose, to
week 9 post-dose was noted, which manifested the
CCl4-induced metabolic alterations. In the YGJD
group, the metabolic pattern of week 1 post-dose
obviously deviated from that of week 0 pre-dose.
The metabolic patterns on week 8 and week 9
showed the reversion tendency towards the week 0
pre-dose state with the treatment of YGJD. This
outcome suggested that YGJD has the potential to
correct those deviations induced by CCl4 exposure.
Figure 6 Two hundred permutations were performed, and the resulting R2and Q2 values were plotted. (Green triangle): R2; (blue square):
Q2. The green line represents the regression line for R2 and the blue line for Q2.
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Liver fibrosis occurs as a consequence of dynamic
wound-healing response to acute or chronic hepatocellu-
lar damage(s), and it pose a high threat with significant
morbidity and mortality [29]. Currently, no acceptable
therapeutic strategies exist. There is a huge need and
great significance to search for effective ways to inhibit
liver fibrosis and prevent the development of cirrhosis
[30]. The present study demonstrated that YGJD, a stan-
dardized extract of a TCM formula, had therapeutic ef-
fects on CCl4-induced liver fibrosis in rats.
An animal model of CCl4-induced liver fibrosis was
established, and in vivo anti-fibrotic effects of YGJD were
investigated. The histological results showed that the nor-
mal structure of lobules was destroyed, and pseudolobules
were formed. Moreover, the increased hydroxyproline
content in liver, the key characteristic component of colla-
gen [31], also confirmed the hepatic fibrogenesis in rats.
There was a significant increase in the levels of ALT, AST,
GGT, TBil as well as decrease in serum Alb content on
exposure to CCl4, indicating considerable hepatocellular
injury. YGJD effectively reduced the elevated levels ofhydroxyproline content, serum ALT, AST, GGT and TBil,
and enhance the reduced serum Alb levels which were
lower in CCl4-treated rats. The histopathological analysis
suggested that YGJD obviously alleviated the degree of
CCl4-induced liver fibrosis. Our earlier study showed that
effect of YGJD on liver fibrosis was associated with its
ability to improve the activity of matrix metalloproteinase
(MMP)-9 and contents of MMP-13, TIMP-2 and hepato-
cyte growth factor alpha (HGFalpha) and decrease the
activity of MMP-2 and contents of α-SMA, TIMP-1,
caspase-12 and hepatocyte apoptotic index [12]. In
addition, it also manifested that YGJD blocked the increase
of transforming growth factor beta (TGF-β), and up-
regulation of procollagen alphaI (data not shown). YGJD
contains key bioactive compounds that include ferulic acid
and catalpol. The present study showed that sodium
ferulate (a sodium salt of ferulic acid) markedly inhibited
HSC activation and collagen production, increased MMP-
1 expression, and decreased TIMP-1expression [32]. An-
other study has reviewed that catalpol prevents d-galactose
induced mitochondrial dysfunction in mice involving
inhibiting of nitric oxide synthase activity, production of
Table 2 Identification results of metabolites in this study







Indole-3-carboxylic acid ↑* ↓ NS Tryptophan metabolism
Butanedioic acid ↑* ↓# NS Energy metabolism
Glycine ↓* ↑ NS P450 metabolism
Leucine ↓* ↑ NS Amino acid metabolism
Phenol ↓* ↑ NS Flora metabolism
Proline ↓** ↑# NS Amino acid metabolism
Citrate ↑* ↓## NS Energy metabolism
Hippuric acid ↑* ↓# NS P450 metabolism
Glutamate ↑* ↓ NS Amino acid metabolism
Hexadecanoic acid ↑* ↓# NS Fatty acid metabolism
Oleic acid ↓* ↑ NS Fatty acid metabolism
Octadecenoic acid ↓* ↑ △ Fatty acid metabolism
Lysine ↓** ↑ △ Amino acid metabolism
Tryptophan ↓* ↑# NS Tryptophan metabolism
“↓” indicates relative decrease, “↑” indicates relative increase, *P < 0.05, ** P < 0.01 compared with control group; ## P < 0.01, # P < 0.05 compared with model
group; △P < 0.05 compared with control group; NS indicates Non-significant. Results were expressed as x þ =−SEð Þ, units were mg/mL urine sample, which are
provided in the Additional file 1.
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activities and MMP level [33]. The above data indicated
that the potential of YGJD as an effective drug against hep-
atic fibrosis.
Apart from the biochemical and histological effects of
YGJD, the GC/MS coupled with pattern recognition ana-
lysis were studied, and changes in urine metabolic profile
were explored. The results of GC/MS-based metabonomic
analysis of urine samples indicate that YGJD administra-
tion has a clear impact on the CCl4-induced metabolite
disorder and can redress the perturbation of metabolites.
These significantly changed metabolites may be explain
the action mechanism of YGJD.
Butanedioic acid and citrate are the intermediates of tri-
carboxylic acid (TCA) cycle and provide an easy energy
supply for the body. In this study, butanedioic acid and
citrate were obviously increased in model group compared
with those in the control group, suggesting the dysfunc-
tion of energy metabolism. Oxidative stress has been
shown to be a major molecular mechanism involved in
CCl4 toxicity [34] and is connected with chronic liver dis-
eases of many causes [35]. In the presence of oxidative
stress, mitochondrial TCA cycle is slowed down in that
cellular regulation reduce the generation of free radicals
[36]. We infer that the increase of butanedioic acid and
citrate is due to the dysfunction of TCA. It has been
reported that catalpol, one of the active compounds of
YGJD, is a natural component of Rehmannia glutionsa,
has protective effects on energy metabolism disturbance
[37]. Our previous study showed that YGJD improved
hepatic glucose metabolism [38]. In this work, YGJDintervention evidently decreased the levels of butanedioic
acid and citrate, and it recovered the tendency towards
the normal levels, indicating that YGJD may protect
against CCl4-induced fibrosis by regulation perturbations
of energy metabolism (Figure 8).
As displayed in Table 2, the free fatty acids such as
hexadecanoic acid, oleic acid, and octadecenoic acid,
were significantly changed in model group compared
with the control group. It has been reported that some
free fatty acids had strong cytotoxicity, which may im-
pair the cell membrane, mitochondria, and lysosomal
membranes, inducing intracellular micro-organ damage,
and significantly improve the toxicity of cytokines, lead-
ing to the liver degeneration, inflammatory cell infiltra-
tion and fibrosis. This indicates that the formation of
CCl4–induced liver fibrosis is closely related to the
changes of free fatty acids [39,40]. Our results demon-
strated YGJD treatment could restore the altered levels
of these three metabolites in model group rats towards
those in control group rats. Ferulic acid, another active
compound of YGJD, is isolated from Angelica sinensis,
has potential antioxidant capacity and terminate free
radical chain reactions,and effectively scaveng deleteri-
ous radicals [41]. Moreover, ferulic acid can prevent cell
damage caused by O2-, and in particular by -OH and
NO, in living systems [42]. From the above literature
and results, it is well understood that fatty acids are im-
portant for the recovery of damaged livers in rats, and
YGJD alleviates the consequences of liver fibrosis that
may be associated with abnormalities in free fatty acid
metabolisms (Figure 8).
Figure 7 Score plot from mean scores value of PCA derived from the GC/MS profiles of urine samples obtained from rats with control
group (■), model group (red bullet) and YGJD group (green triangle) at weeks 0, 6, 8 and 9. The plot depicts a time- related trajectory of
metabolite patterns at different time points.
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decreased, and hippuric acid was significantly increased
when compared with the control group (Table 2). Glycine
is essential for hippuric acid production in the liver along
with benzoic acid under cytochrome P450 catalysis [43].
Therefore, the alterations of hippuric acid and glycine
concentrations in the model group indicate the changes in
the activity of cytochrome P450 to some extent, and cyto-
chrome P450 activity and liver fibrosis formation has a
high degree of correlation [4]. In our research, YGJD regu-
lated the metabolite level of glycine and hippuric acid.
The results of histology and metabonomics demonstrated
that the anti-fibrotic effect of YGJD might be associated
with its activity of cytochrome P450 (Figure 8).
In the model group, leucine, lysine, and proline were
significantly decreased, and, glutamate was significantly
increased than in the control group, which suggested the
abnormality of amino acid metabolism. It is reported that
liver diseases are often associated with inflammation and
oxidative stress, and these conditions facilitate the forma-
tion of advanced glycation end products, which are known
to impair protein function and promote inflammation [44].
Amino acids are substrates for protein synthesis [45]. When
the liver fibrosis models were made in this study, CCl4 in-
toxication could be attenuated amino acid uptake and pro-
teins synthesis [46]. Leucine, is one of the branched-chain
amino acids (BCAA) [47]. BCAA-enriched nutrients were
found to reduce oxidative stress and stimulate antioxidantDNA repair in a rat model of CCl4-induced liver injury
[48]. In addition, glutamate is one of three amino acids of
the GSH biosynthesis, and GSH is a major antioxidant,
which quenches the endogenous oxidant species and
attacks exogenous oxidative stress and has been seen as a
major molecular mechanism in CCl4 toxicity [49]. Previ-
ous studies reported that ferulic acid protects from CCl4-
induced acute liver injury through reduction of oxidative
damage and inflammatory signaling pathways [50]. YGJD
intervention of CCl4-treated rats showed a tendency of
bringing the level of leucine, lysine, proline, and glutamate
to normal level or close to normal level. Based on these
findings, it is likely that the antifibrotic effect of YGJD
might be concerned with its antioxidative activity through
modulating the perturbed amino acid metabolism path-
way (Figure 8).
Tryptophan is an essential amino acid which cannot
be synthesized by the body, and it must be drawn from
the food. It is the precursor of serotonin, an important
neurotransmitter, and it plays a big role in the process of
protein synthesis and is involved in some pathological
processes [45,51]. Previous research showed tryptophan
administration promotes the reversion of CCl4- induced,
pre-established chronic liver injury, and suggests that
tryptophan exerts this effect by enhancing several liver
dysfunction parameters associated with chronic liver in-
jury and also by stimulating hepatic protein synthesis
[52]. In our study, the level of tryptophan in the urine is
Figure 8 The perturbed metabolic pathways in response to CCl4 exposure and YGJD treatment. The levels of changed metabolites in model
group compared to control group were labeled with (↓) down-regulated or (↑) up-regulated; *metabolites in abnormal could be regulated by YGJD.
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The tryptophan pathway could possibly be changed
during the formation of liver fibrosis. Furthermore,
indole-3-carboxylic acid level in the urine of model rats
was markedly elevated compared with that of control
rats. Up-regulation of indole-3-carboxylic acid might be
the result of the tryptophan abnormal metabolism [53].
In YGJD group, the concentration of tryptophan and
indole-3-carboxylic acid returned close to normal, indi-
cating the therapeutic effects of YGJD may rely on the
regulation of the dysfunction of tryptophan metabolism
(Figure 8).
Phenol is considered as one the metabolites of gut
microflora and derives from the bacterial aromatic
amino acids and polyphenols fermentation that were
from polyphenols in food and food protein decompos-
ition [54]. Gut microflora play a big role in nutrition
and disease prevention, and there is an intensive con-
nection between liver and gut. Abnormal bile due to
liver damage leads to the dysfunction of intestinalbarrier,and thus, may cause the changes in intestinal
flora or composition, or even bacterial translocation
and its metabolite changes [55]. A recent publication
reported that the gut microbiota alterations were asso-
ciated with the development of an inflammatory environ-
ment, fibrosis progression and bacterial translocation in
CCl4-treated mice [56]. Changes in these endogenous
metabolites might probably be due to gut microflora al-
terations caused by CCl4 exposure. In clinical studies,
Escherichia coli Nissle were administered to patients with
liver cirrhosis, which confirmed that probiotics might
reduce the level of endotoxin and improve liver functions.
The restoration of normal bacterial flora in the gut
resulted in lower absorption of toxic metabolites and
endotoxins in treated patients [57]. In our work, in the
model group, phenol was significantly decreased com-
pared with the control group. YGJD group has higher
levels of phenol compared with the model group. In
conclusion, CCl4 could affect gut microflora and change
endogenous metabolites. From the results, it is suggested
Gou et al. BMC Complementary and Alternative Medicine 2013, 13:123 Page 11 of 12
http://www.biomedcentral.com/1472-6882/13/123that YGJD may exert its anti-fibrotic efficacy by regulating
the gut flora (Figure 8).Conclusions
This is the first study to evaluate the urine metabolic
profile changes of CCl4-induced liver fibrosis in rats and
examine the intervention effects of YGJD through a
metabonomic based GC/MS method. Multivariate statis-
tical analysis showed that the separation of model and
control groups was clearly achieved. YGJD group was
mainly located between these two groups and exhibited
a tendency of recovering to control group. Fourteen sig-
nificantly changed metabolites related to antifibrotics by
YGJD were identified, and they could be reversed by YGJD
treatment. This indicated that the therapeutic effect of
YGJD on liver fibrosis may involve in regulating the dys-
function of energy metabolism, amino acid metabolism,
tryptophan metabolism, cytochrome P450 metabolism,
and gut microflora metabolism. This work confirmed that
a metabonomic method can be used to study the efficacy
and mechanism of complex TCM in a dynamic and non-
invasive way. Further investigations using different animal
models and hepatotoxic agents are recommended in the
future using metabonomic approach to get more data on
the reliability of YGJD in chronic liver diseases.Additional file
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